A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 17721-17729

  Zhou, Huancheng ^a,b   Wang, Jie ^a   Peng, Guangfu ^b   Song, Yue ^b   Zhang, Caiyun ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Department of Second Urology   (China)

Author keywords

Hepatocellular carcinoma; Histone deacetylase 1; shRNA lentiviral system

Indexed keywords

CYCLIN D1; HISTONE DEACETYLASE 1; LENTIVIRUS VECTOR; MESSENGER RNA; PROTEIN P21; PROTEIN P27; PROTEIN ZO1; SHORT HAIRPIN RNA; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER GROWTH; CELL INVASION ASSAY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LENTIVIRUS INFECTION; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84949662280     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. [1] World Health Organization. Cancer (fact sheet no.297). 2015; available on http://www.who.int/mediacentre/factsheets/fs297/en/.
2. [2] Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, Monden M and Matsuura N. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001; 8: 903-907.
3. [3] Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
4. [4] Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
5. [5] Waly Raphael S, Yangde Z and Yu Xiang C. Hepatocellular Carcinoma: Focus on Different Aspects of Management. ISRN Oncology 2012; 2012: 421673.
6. [6] Llovet JM, Burroughs A and Bruix J. Hepato-cellular carcinoma. Lancet 2003; 362: 1907-1917.
7. [7] Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
8. [8] Dumitrescu RG. Epigenetic targets in cancer epidemiology. Methods Mol Biol 2009; 471: 457-467.
9. [9] Jaenisch R and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 Suppl: 245-254.
10. [10] Seo J, Min SK, Park HR, Kim DH, Kwon MJ, Kim LS and Ju YS. Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. J Breast Cancer 2014; 17: 323-331.
11. [11] Ropero S and Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19-25.
12. [12] Peng L and Seto E. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 2011; 206: 39-56.
13. [13] Shankar S and Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298.
14. [14] Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M and Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007; 72: 69-74.
15. [15] Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D and Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011; 459: 129-139.
16. [16] Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG and Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233-240.
17. [17] Papeleu P, Loyer P, Vanhaecke T, Elaut G, Geerts A, Guguen-Guillouzo C and Rogiers V. Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. J Hepatol 2003; 39: 374-382.
18. [18] Yamashita Y, Shimada M, Harimoto N, Riki-maru T, Shirabe K, Tanaka S and Sugimachi K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003; 103: 572-576.
19. [19] Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM and Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2005; 42: 210-217.
20. [20] Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B and June CH. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006; 103: 17372-17377.
21. [21] Debbie M and Brooks SA. In Vitro Invasion Assay Using Matrigel®. In: editors. Metastasis Research Protocols. Springer; 2001. pp. 61-70.
22. [22] Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812-821.
23. [23] Rodriguez R and Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17: 402-412.
24. [24] Moller MB. P27 in cell cycle control and cancer. Leuk Lymphoma 2000; 39: 19-27.
25. [25] Kalluri R and Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
26. [26] Ebnet K, Schulz CU, Meyer Zu Brickwedde MK, Pendl GG and Vestweber D. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J Biol Chem 2000; 275: 27979-27988.
27. [27] Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622-634.
28. [28] Leader M, Collins M, Patel J and Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology 1987; 11: 63-72.
29. [29] Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, Smith R, Michaelides MR, Davidsen SK and Glaser KB. Expression and functional characterization of recombinant human HD-AC1 and HDAC3. Life Sci 2004; 74: 2693-2705.
30. [30] Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL and Chen CS. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007; 46: 1119-1130.
31. [31] Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J and Zheng SS. Identification of histone deacetylase 3 as a biomarker for tu-mor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010; 5: e14460.
32. [32] Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C and Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784-4795.
33. [33] Zhai X, Zhu H, Wang W, Zhang S, Zhang Y and Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol 2014; 31: 970.
34. [34] von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G and Saur D. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009; 137: 361-371, 371.e361-365.
35. [35] Xu J, Lamouille S and Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.